StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Kalaris Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $32.87M, down 39.5% year over year. For fiscal 2025 it was $30.75M, down 31.7% from the year before. The highest annual figure on record is $133.07M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.75M-31.7%
FY2024Dec 31, 2024$45.04M-66.2%
FY2023Dec 31, 2023$133.07M+11.9%
FY2022Dec 31, 2022$118.87M-1.5%
FY2021Dec 31, 2021$120.74M+143.1%
FY2020Dec 31, 2020$49.66M+205.7%
FY2019Dec 31, 2019$16.25M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.02M+6.8%
Q1 FY2026Mar 31, 2026$7.57M+25.6%
Q4 FY2025Dec 31, 2025$7.16M+85.9%
Q3 FY2025Sep 30, 2025$9.13M-74.7%
Q2 FY2025Jun 30, 2025$8.44M+162.8%
Q1 FY2025Mar 31, 2025$6.03M+207.5%
Q4 FY2024Dec 31, 2024$3.85M-88.5%
Q3 FY2024Sep 30, 2024$36.02M+5.5%
Q2 FY2024Jun 30, 2024$3.21M-90.8%
Q1 FY2024Mar 31, 2024$1.96M-93.6%
Q4 FY2023Dec 31, 2023$33.37M+17.4%
Q3 FY2023Sep 30, 2023$34.16M+13.8%
Q2 FY2023Jun 30, 2023$34.82M+11.0%
Q1 FY2023Mar 31, 2023$30.72M+5.7%
Q4 FY2022Dec 31, 2022$28.42M-31.7%
Q3 FY2022Sep 30, 2022$30.00M-9.2%
Q2 FY2022Jun 30, 2022$31.38M+22.2%
Q1 FY2022Mar 31, 2022$29.07M+42.5%
Q4 FY2021Dec 31, 2021$41.60M+148.3%
Q3 FY2021Sep 30, 2021$33.06M+92.4%
Q2 FY2021Jun 30, 2021$25.68M+189.0%
Q1 FY2021Mar 31, 2021$20.39M+198.2%
Q4 FY2020Dec 31, 2020$16.76M+150.6%
Q3 FY2020Sep 30, 2020$17.18M+203.8%
Q2 FY2020Jun 30, 2020$8.89M+222.5%
Q1 FY2020Mar 31, 2020$6.84M–
Q4 FY2019Dec 31, 2019$6.69M–
Q3 FY2019Sep 30, 2019$5.66M–
Q2 FY2019Jun 30, 2019$2.76M–

More Kalaris Therapeutics figures

See a number that looks wrong?